S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

OTCMKTS:PCFPApotheca Biosciences Stock Price, Forecast & News

$0.03
0.00 (0.00 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range
$0.01
MA: $0.02
$0.20
52-Week Range
$0.12
Now: $0.03
$0.94
VolumeN/A
Average Volume45,057 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulation, and delivery technologies for the healthcare and consumer care industry. The company is based in the United States.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Packaged Foods
Sub-IndustryN/A
Current SymbolOTCMKTS:PCFP
CUSIPN/A
CIKN/A
Phone727-228-3994

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PCFP News and Ratings via Email

Sign-up to receive the latest news and ratings for PCFP and its competitors with MarketBeat's FREE daily newsletter.

Apotheca Biosciences (OTCMKTS:PCFP) Frequently Asked Questions

How has Apotheca Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Apotheca Biosciences' stock was trading at $0.0190 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCFP stock has increased by 31.6% and is now trading at $0.0250. View which stocks have been most impacted by Coronavirus.

Has Apotheca Biosciences been receiving favorable news coverage?

Headlines about PCFP stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apotheca Biosciences earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Apotheca Biosciences.

Who are some of Apotheca Biosciences' key competitors?

What other stocks do shareholders of Apotheca Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apotheca Biosciences investors own include Cronos Group (CRON), Smart Global (SGH), America First Multifamily Investors (ATAX), Sprott Resource (SCP), Tilray (TLRY), Allena Pharmaceuticals (ALNA), Canopy Growth (CGC), General Electric (GE), Kinder Morgan (KMI) and Sorrento Therapeutics (SRNE).

Who are Apotheca Biosciences' key executives?

Apotheca Biosciences' management team includes the following people:
  • Dr. P. C. Sundareswaran, Chairman & CEO
  • Mr. Charles K. Dargan II, Chief Financial Officer (Age 63)
  • Ms. Deirdre Fernandes, COO & Director
  • Mr. John Verghese, CTO & Director (Age 58)
  • Mr. Craig Huffman, Legal Council

What is Apotheca Biosciences' stock symbol?

Apotheca Biosciences trades on the OTCMKTS under the ticker symbol "PCFP."

How do I buy shares of Apotheca Biosciences?

Shares of PCFP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apotheca Biosciences' stock price today?

One share of PCFP stock can currently be purchased for approximately $0.03.

What is Apotheca Biosciences' official website?

The official website for Apotheca Biosciences is www.cannabisleafinc.co.

How can I contact Apotheca Biosciences?

The company can be reached via phone at 727-228-3994.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.